ViewRay’s MRIdian Is Promising, But Losses Mount

  • The company’s MRIdian offers more accurate radiotherapy for cancer patients but they won’t have the field to themselves.
  • Worries about the viability of the MRIdian are unfounded as a competitor takes a financial stake in the company.
  • However, the case for investors is far from clear cut as order growth slows and losses, cash bleed, and dilution mount so we’ll pass on this one.

Source: ViewRay’s MRIdian Is Promising, But Losses Mount – ViewRay, Inc. (NASDAQ:VRAY) | Seeking Alpha